HLHuayue Lin

Huayue Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huayue Lin has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Minghui Wang

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    15 shared publications
  • Duoguang Wu

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    9 shared publications
  • Kai Lei

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    9 shared publications
  • Ruihao Liang

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    8 shared publications
  • Wenjian Wang

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    8 shared publications
  • Xueting Hu

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    7 shared publications

Latest Publications

  • Open Access

    DNA methylation biomarkers-based method for the differential diagnosis of multiple lung cancers

    by Ke Xu, Binghua Tan, Ruihao Liang, Jialu Liang, Zhanghai He, Jianqun He, Yiming Zhong, Xueting Hu, Kai Lei, Hanlin Lu, et al.

  • Open Access

    Prostaglandin E2 induces dendritic cell dysfunction in skin involvement of breast cancer

    by Jiawen Wang, Xiaoming Zhong, Xu Liu, Zhiyun Qian, Jingkun Zhu, Huayue Lin, Jiahui Zhang, Wei Zhang, Sicong Du, Linbin Yang, et al.

    The skin involvement (SI) of breast cancer exhibits suboptimal to standard treatment and poor prognosis. Dendritic cells (DCs) are essential to maintain immune homeostasis. However, the role of cutaneous DCs in skin lesions of breast cancer remains elusive, limiting the development of therapeutic approaches. Here, skin tissues from 47 breast cancer patients were analyzed for different immune cell infiltration, showing a significant reduction in DC number and activation in lesional skin. Transcriptome analyses, in vitro antigen processing and T lymphocyte priming assays of primary cutaneous DCs from breast cancer patients corroborated impaired antigen processing and T lymphocyte priming in lesional skin. Mechanistically, metabolomic analyses profiled the microenvironment of lesional and non-lesional skin and revealed increased prostaglandin E 2 (PGE 2 ) levels in the lesional skin, which could inhibit DC activation. Inhibiting PGE 2 in vivo effectively restored the activation of DCs and CD8 + T lymphocytes and attenuated the skin involvement in mouse models of different cancer types. Clinically, the PGE 2 levels were negatively correlated with DC infiltration in the skin of breast cancer patients, and low PGE 2 expression and high DC activation were associated with better patient outcomes. Collectively, our study reveals that PGE 2 induces DC dysfunction in the skin involvement of breast cancer, highlighting the potential of targeting PGE 2 for managing patients with skin involvement.


  • Open Access

    Single-cell analysis reveals transcriptomic features and therapeutic targets in primary pulmonary lymphoepithelioma-like carcinoma

    by Binghua Tan, Ke Xu, Yingcheng Lyu, Yicheng Liang, Ruihao Liang, Kai Lei, Jialu Liang, Jing Huang, Kefeng Wang, Duoguang Wu, et al.

    Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of non-small-cell lung cancer. Duo to the current lack of precise targeted therapies, there is an urgent need to identify novel therapeutic targets. In this study, we perform single-nucleus transcriptome analysis on PPLELC samples to reveal the molecular tumor heterogeneity and characterize the functional states of immune cells within the tumor microenvironment. We identify a critical malignant subpopulation of PPLELC characterized by elevated expression of AKT3 and FGFR2. Higher expression levels of AKT3 and FGFR2 are associated with poorer patient outcomes. Moreover, treatment with either an AKT3 inhibitor or an FGFR2 inhibitor significantly attenuates tumor progression in patient-derived xenograft models. Our findings highlight AKT3 and FGFR2 as potential therapeutic targets and prognostic biomarkers, providing valuable insights for the development of rational targeted therapies and immunotherapeutic strategies.


  • RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC

    by Wei Zhang, Jiawen Wang, Jialu Liang, Zhanghai He, Kefeng Wang, Huayue Lin

    Background Although immune checkpoint inhibitors (ICIs) have been successfully utilized in patients with non-small cell lung cancer (NSCLC), EGFR-mutated patients didn’t benefit from ICIs. The underlying mechanisms for the poor efficacy of this subgroup remain unclear. Methods CD8+T cells cytotoxicity, DCs phagocytosis and immunofluorescence assay were applied to examine the immunosuppressive microenvironment of NSCLC. m6A RNA immunoprecipitation, luciferase assay and immunohistochemistry were used to explore the relationship between CD47 and ALKBH5 in EGFR-TKI resistant NSCLC. Autochthonous EGFR-driven lung tumor mouse model and PDXs were performed to explore the therapeutic potential of CD47 antibody and EGFR-TKI combination. Results We found that EGFR-TKI resistance promoted a more immunosuppressive tumor microenvironment and inhibited anti-tumor functions of CD8+ T cells. Mechanistically, the m6A eraser ALKBH5 was inhibited in EGFR-TKI resistant NSCLC, which subsequently upregulates CD47 by catalyzing m6A demethylation and causes immunosuppression. Combined treatment with EGFR-TKI and inhibitors of CD47 enhances antitumor immunity and EGFR-TKI efficacy in vivo. Conclusions Collectively, our findings reveal the possible underlying mechanism for poor immune response of ICIs in EGFR-TKI resistant NSCLC and provide preclinical evidence that targeted therapy combined with innate immune checkpoint blockade may provide synergistic effects in NSCLC treatment.


  • Open Access

    Tumor-derived apoptotic extracellular vesicle-mediated intercellular communication promotes metastasis and stemness of lung adenocarcinoma

    by Xiaotian He, Yiyang Ma, Yingsheng Wen, Rusi Zhang, Dechang Zhao, Gongming Wang, Weidong Wang, Zirui Huang, Guangran Guo, Xuewen Zhang, et al.

    Apoptosis has long been recognized as a significant mechanism for inhibiting tumor formation, and a plethora of stimuli can induce apoptosis during the progression and treatment of tumors. Moreover, tumor-derived apoptotic extracellular vesicles (apoEVs) are inevitably phagocytosed by live tumor cells, promoting tumor heterogeneity. Understanding the mechanism by which apoEVs regulate tumor cells is imperative for enhancing our knowledge of tumor metastasis and recurrence. Herein, we conducted a series of in vivo and in vitro experiments, and we report that tumor-derived apoEVs promoted lung adenocarcinoma (LUAD) metastasis, self-renewal and chemoresistance. Mechanistically, we demonstrated that apoEVs facilitated tumor metastasis and stemness by initiating the epithelial-mesenchymal transition program and upregulating the transcription of the stem cell factor SOX2. In addition, we found that ALDH1A1, which was transported by apoEVs, activated the NF-κB signaling pathway by increasing aldehyde dehydrogenase enzyme activity in recipient tumor cells. Furthermore, targeting apoEVs-ALDH1A1 significantly abrogated these effects. Collectively, our findings elucidate a novel mechanism of apoEV-dependent intercellular communication between apoptotic tumor cells and live tumor cells that promotes the formation of cancer stem cell-like populations, and these findings reveal that apoEVs-ALDH1A1 may be a potential therapeutic target and biomarker for LUAD metastasis and recurrence.


  • Open Access

    The FGF6 amplification mutation plays an important role in the progression and treatment of malignant meningioma

    by Ruihao Liang, Binhua Tan, Kai Lei, Ke Xu, Jialu Liang, Jing Huang, Yicheng Liang, Jintao Huang, Liwen Zhang, Xiaoliang Shi, et al.


  • Corrigendum to “CCL18-induced HOTAIR upregulation promotes malignant progression in esophageal squamous cell carcinoma through the miR-130a-5p-ZEB1 axis” [Cancer Lett. 460 (2019) 18–28]

    by Wenjian Wang, Duoguang Wu, Xiaotian He, Xueting Hu, Chuwen Hu, Zhiwen Shen, Jiatong Lin, Zihao Pan, Zhanghai He, Huayue Lin, et al.

  • Open Access

    CircPDE5A-encoded novel regulator of the PI3K/AKT pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1

    by Kai Lei, Ruihao Liang, Jialu Liang, Nan Lu, Jing Huang, Ke Xu, Binghua Tan, Kexi Wang, Yicheng Liang, Wenjian Wang, et al.

    Background: Esophageal squamous cell carcinoma (ESCC) is a common gastrointestinal tumor and has become an important global health problem. The PI3K/AKT signaling pathway plays a key role in the development of ESCC. CircRNAs have been reported to be involved in the regulation of the PI3K/AKT pathway, but the underlying mechanisms are unclear. Therefore, this study aimed to identify protein-coding circRNAs and investigate their functions in ESCC. Methods: Differential expression of circRNAs between ESCC tissues and adjacent normal tissues was identified using circRNA microarray analysis. Thereafter, LC–MS/MS was used to identify circPDE5A-encoded novel protein PDE5A-500aa. Molecular biological methods were used to explore the biological functions and regulatory mechanisms of circPDE5A and PDE5A-500aa in ESCC. Lastly, circRNA-loaded nanoplatforms were constructed to investigate the therapeutic translation value of circPDE5A. Results: We found that circPDE5A expression was down-regulated in ESCC cells and tissues and that it was negatively associated with advanced clinicopathological stages and poorer prognosis in ESCC. Functionally, circPDE5A inhibited ESCC proliferation and metastasis in vitro and in vivo by encoding PDE5A-500aa, a key regulator of the PI3K/AKT signaling pathway in ESCC. Mechanistically, PDE5A-500aa interacted with PIK3IP1 and promoted USP14-mediated de-ubiquitination of the k48-linked polyubiquitin chain at its K198 residue, thereby attenuating the PI3K/AKT pathway in ESCC. In addition, Meo-PEG-S–S-PLGA-based reduction-responsive nanoplatforms loaded with circPDE5A and PDE5A-500aa plasmids were found to successfully inhibit the growth and metastasis of ESCC in vitro and in vivo. Conclusion: The novel protein PDE5A-500aa encoded by circPDE5A can act as an inhibitor of the PI3K/AKT signaling pathway to inhibit the progression of ESCC by promoting USP14-mediated de-ubiquitination of PIK3IP1 and may serve as a potential target for the development of therapeutic agents. Graphical The novel protein PDE5A-500aa encoded by circPDE5A can act as an inhibitor of the PI3K/AKT signaling pathway to inhibit the progression of esophageal squamous cell carcinoma.


  • Open Access

    Comparative analysis of single-cell transcriptome reveals heterogeneity in the tumor microenvironment of lung adenocarcinoma and brain metastases

    by Jialu Liang, Ruihao Liang, Kai Lei, Jing Huang, Huayue Lin, Minghui Wang

    Purpose: Solid tumors such as lung adenocarcinoma include not only the tumor cells but also the microenvironment in which the tumor cells continuously interact with each other. An in-depth understanding of the oncological features and tumor microenvironment (TME) of lung adenocarcinoma and brain metastases at the single-cell level could provide new therapeutic strategies for brain metastases from lung adenocarcinoma. Methods: To solve this problem, we performed single-cell RNA sequencing (scRNA-seq) analysis on 15 lung adenocarcinoma samples and 10 brain metastasis samples. Results: A total of 86,282 single cells were obtained and divided into 8 cell types, including epithelial cells, endothelial cells, fibroblasts, oligodendrocytes, T/NK cells, B cells, mast cells, and macrophages. In brain metastases, we found a significantly lower proportion of T/NK cells and mast cells, and more severe immune dysregulation. In addition, we found a subpopulation of macrophages with high expression of metastasis-promoting-related genes enriched in brain metastatic tissues. Moreover, in brain metastases, we found a significantly increased proportion of myofibroblastic cancer-associated fibroblasts (myCAFs) and a higher angiogenic capacity of endothelial cells. Epithelial cells in brain metastases were more malignant and underwent genomic reprogramming. Next, we found that DNA damage-inducible transcript 4 (DDIT4) expression was upregulated in epithelial cells in brain metastases and was associated with poor prognosis. Finally, we experimentally validated that the downregulation of DDIT4 inhibited the proliferation, migration, and invasion of lung cancer cells. Conclusions: This study depicts a single-cell atlas of lung adenocarcinoma and brain metastases by scRNA-seq and paves the way for the development of future therapeutic targets for brain metastases from lung cancer.